养生
乳腺癌
医学
肿瘤科
新辅助治疗
化疗
佐剂
内科学
保乳手术
内分泌系统
癌症
激素
乳房切除术
作者
Marianna Sirico,Alessandra Virga,Benedetta Conte,Milena Urbini,Paola Ulivi,Caterina Gianni,Filippo Merloni,Michela Palleschi,Marco Gasperoni,Annalisa Curcio,Debjani Saha,Giuseppe Buono,Montserrat Muñoz,Ugo De Giorgi,Francesco Schettini
标识
DOI:10.1016/j.critrevonc.2022.103900
摘要
Neoadjuvant endocrine treatment (NET) associates to satisfactory rates of breast conservative surgery and conversions from inoperable to operable hormone receptor-positive (HR+)/HER2-negative breast cancer (BC), with less toxicities than neoadjuvant chemotherapy (NACT) and similar outcomes. Hence, it has been proposed as a logical alternative to NACT in patients with HR+/HER2- BC candidate to a neoadjuvant approach. Nevertheless, potential barriers to the widespread use of NET include the heterogeneous nature of patient response coupled with the long duration needed to achieve a clinical response. However, interest in NET has significantly increased in the last decade, owing to more in-depth investigation of several biomarkers for a more adequate patient selection and on-treatment benefit monitoring, such as PEPI score, Ki67 and genomic assays. This review is intended to describe the state-of-the-art regarding NET, its future perspectives and potential integration with molecular biomarkers for the optimal selection of patients, regimen and duration of (neo)adjuvant treatments.
科研通智能强力驱动
Strongly Powered by AbleSci AI